Anti-Venom Market Report by Type (Polyvalent Anti-Venom and Monovalent Anti-Venom), Animal Type (Wheat Snake, Scorpion, Spider, and Others), End User (Clinics, Hospitals, Ambulatory Surgical Centers, and Others), Region and Company Analysis 2024-2032
Buy NowGlobal Anti-Venom Market Analysis
Global Anti-Venom Market, valued at US$ 1.11 Billion in 2023, is projected to grow at a CAGR of 6.46% between 2024 and 2032, reaching an estimated worth of US$ 1.95 Billion by 2032.
The demand for anti-venom is progressively growing as venomous snakebites pose an international public health issue. Anti-venom, derived from animal antibodies, is the primary treatment for snakebite envenomation, correctly neutralizing venom toxins. Access to powerful anti-venom is essential, predominantly in rural areas of Africa, Asia, and Latin America. However, challenges such as insufficient distribution, affordability, and varying efficacy of available remedies underscore the pressing need for stepped-forward accessibility and development of novel anti-venom formulations.
Anti-Venom Market Trends
The growing number of snakebite sufferers is crucial in improving anti-venom market growth for remedies. According to the World Health Organization, 5.4 million humans worldwide are bitten by snakes each year, resulting in 1.8 to 2.7 million cases of envenomation. Furthermore, approximately 81,410 to 137,880 people die yearly because of snakebites, with three times as many going through amputations and everlasting disabilities. Venomous snakebites can result in paralysis, deadly hemorrhage, kidney failure, tissue damage, and limb amputation, mainly affecting agricultural workers and children, who frequently experience more severe results due to their smaller body mass.
The governments, non-profit companies, and healthcare providers strive to enhance access to anti-venom in excessive-risk areas, driving the global anti-venom market forward. For example, the World Health Organization (WHO) has installed a Technical and Scientific Advisory Group to formulate public-sector Target Product Profiles (TPPs) for addressing snakebite envenoming. Supported by the Drugs for Neglected Disease Initiative (DNDi), this initiative guarantees access to safe, effective, inexpensive, and easy treatments for all sufferers requiring them.
Moreover, significant investment in research and development (R&D) endeavors toward creating modern anti-venom merchandise extensively affects the expansion of the anti-venom market. Notably, findings from the latest studies by the Liverpool School of Tropical Medicine in 2023 display promising breakthroughs in the anti-venom domain. Their observation shows that novel drug combinations hold the promise of protecting snakebite sufferers from the severe and life-changing consequences of venom toxicity, thereby fostering optimism for more significant treatment outcomes.
Further, introducing diverse speedy snake venom detection kits and using quick enzyme immunoassays to perceive snake venom through samples from bite sites, urine, plasma, blood, or different physical fluids is driving the market boom. The mergers, acquisitions, multiplied investments, and collaborations with other companies also bolster the worldwide market. For instance, in August 2022, Bharat Serums and Vaccines Ltd. (BSV) announced its partnership with the 'Evolutionary Venomics Lab' at the Indian Institute of Science (IISc) Bangalore to develop region-specific antivenoms for snakebites in India.
Polyvalent Anti-Venom segment with multiple uses may become the dominant force in the global anti-venom market
The polyvalent segment might lead the anti-venom market with its extensive-spectrum efficacy towards more than one snake species. These healing materials neutralize pollutants from numerous snakes, providing versatile safety. They effectively treat snakebite sufferers and are designed to be effective towards more than a few venoms. Healthcare providers and patients opt for polyvalent anti-venom because it's more convenient and price-effective, decreasing the need for multiple remedies.
India is expected to have potential significance in the global anti-venom market
The nation Is predicted to play a enormous role inside the global anti venom market due to its excessive prevalence of snakebites and numerous snake species. The World Health Organization (WHO) estimates that every 12 months, approximately five million snakebites arise in India, resulting in up to 2.7 million envenomings and 81,000 to 138,000 deaths. The 'big 4' snake species, consisting of the common krait, Indian cobra, Russell's viper, and saw-scaled viper, account for approximately 90% of snakebites in India. Since snakebites are common in rural regions, there's a considerable call for anti-venom treatments. Additionally, Indian pharmaceutical companies and research institutions are operating on initiatives to enhance anti-venom production and accessibility, similarly contributing to India's potential significance within the international anti venom market.
Global Anti-Venom Market Company News
The companies that make up the global anti-venom market include Bharat Serums and Vaccines Limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CSL Limited, Merck & Co. Inc., Merck KGaA, Pfizer Inc., and Haffkine Bio-Pharmaceutical Corporation Limited.
In March 2024 - India's Union Health Ministry launched a National Action Plan, using a One Health approach to halve snakebite deaths by 2030.
In April 2023 - Terumo India, a subsidiary of Terumo Corporation, launched a unique program for Cathlab Directors in partnership with Executive Education at the Indian School of Business, a top-ranked business school. The program aims to improve the quality of care and efficiency in Cathlabs across India.
In July 2022 - The Antivenom Research and Development Centre (AVRDC) was established at the Institute of Bioinformatics and Applied Biotechnology (IBAB) in Bengaluru's Helix Biotech Park, Electronics City, to enhance antivenom production.
Type – Market breakup in 2 viewpoints:
1. Polyvalent Anti-Venom
2. Monovalent Anti-Venom
Animal Type – Market breakup in 4 viewpoints:
1. WheatSnake
2. Scorpion
3. Spider
4. Others
End-User – Market breakup in 4 viewpoints:
1. Clinics
2. Hospitals
3. Ambulatory Surgical Centers
4. Others
Country – Market breakup of 25 Countries:
1. North America
1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 UAE
5.3 South Africa
All the Key players have been covered from 3 Viewpoints:
• Overview
• Recent Development
• Revenue Analysis
Company Analysis:
1. Bharat Serums and Vaccines Limited (BSV)
2. Boehringer Ingelheim International GmbH
3. Boston Scientific Corporation
4. CSL Limited
5. Merck & Co. Inc.
6. Merck KGaA
7. Pfizer Inc.
8. Haffkine Bio-Pharmaceutical Corporation Limited
Report Details:
| Report Features | Details |
| Base Year | 2023 |
| Historical Period | 2019 - 2023 |
| Forecast Period | 2024 - 2032 |
| Market | US$ Billion |
| Segment Covered | Type, Animal Type, End-User, and Countries |
| Countries Covered | United States, Canada, France, Germany, Italy, Spain, United Kingdom, Belgium, Netherland, Turkey, China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, New Zealand, Brazil, Mexico, Argentina, Saudi Arabia, UAE, and South Africa |
| Companies Covered | Bharat Serums and Vaccines Limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CSL Limited, Merck & Co. Inc., Merck KGaA, Pfizer Inc., and Haffkine Bio-Pharmaceutical Corporation Limited. |
| Customization Scope | 20% Free Customization |
| Post-Sale Analyst Support | 1 Year (52 Weeks) |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Anti-Venom Market
6. Market Share –
6.1 Type
6.2 Animal Type
6.3 End Users
6.4 Country
7. Type –
7.1 Polyvalent Anti-Venom
7.2 Monovalent Anti-Venom
8. Animal Type –
8.1 Snake
8.2 Scorpion
8.3 Spider
8.4 Others
9. End Users –
9.1 Clinics
9.2 Hospitals
9.3 Ambulatory Surgical Centers
9.4 Others
10. Country –
10.1 North America
10.1.1 United States
10.1.2 Canada
10.2 Europe
10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherlands
10.2.8 Turkey
10.3 Asia Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Thailand
10.3.6 Malaysia
10.3.7 Indonesia
10.3.8 Australia
10.3.9 New Zealand
10.4 Latin America
10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina
10.5 Middle East & Africa
10.5.1 Saudi Arabia
10.5.2 UAE
10.5.3 South Africa
11. Porter’s Five Analysis –
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes
12. SWOT Analysis –
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat
13. Key Players
13.1 Bharat Serums and Vaccines Limited (BSV)
13.1.1 Overview
13.1.2 Recent Development
13.1.3 Revenue
13.2 Boehringer Ingelheim International GmbH
13.2.1 Overview
13.2.2 Recent Development
13.2.3 Revenue
13.3 Boston Scientific Corporation
13.3.1 Overview
13.3.2 Recent Development
13.3.3 Revenue
13.4 CSL Limited
13.4.1 Overview
13.4.2 Recent Development
13.4.3 Revenue
13.5 Merck & Co. Inc.
13.5.1 Overview
13.5.2 Recent Development
13.5.3 Revenue
13.6 Merck KGaA
13.6.1 Overview
13.6.2 Recent Development
13.6.3 Revenue
13.7 Pfizer Inc.
13.7.1 Overview
13.7.2 Recent Development
13.7.3 Revenue
13.8 Haffkine Bio-Pharmaceutical Corporation Limited
13.8.1 Overview
13.8.2 Recent Development
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com